Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? (Q37480101)

20 August 2017

1 reference

title

Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? (English)

1 reference

20 August 2017

0 references

0 references

1 reference

Rob Towart

1

1 reference

20 August 2017

Joannes T M Linders

2

1 reference

20 August 2017

An N Hermans

3

1 reference

20 August 2017

Jutta Rohrbacher

4

1 reference

20 August 2017

Henk J van der Linde

5

1 reference

20 August 2017

Martine Ercken

6

1 reference

20 August 2017

Miroslav Cik

7

1 reference

20 August 2017

Peter Roevens

8

1 reference

20 August 2017

Ard Teisman

9

1 reference

20 August 2017

David J Gallacher

10

1 reference

20 August 2017

9 May 2009

1 reference

Journal of Pharmacological and Toxicological Methods

20 August 2017

1 reference

20 August 2017

60

1 reference

20 August 2017

1-10

1 reference

20 August 2017

1

1 reference

Impact of ancillary subunits on ventricular repolarization

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Potassium channel blockade: A mechanism for suppressing ventricular fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Profile of I(Ks) during the action potential questions the therapeutic value of I(Ks) blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

A new type of Ca-channel modulation by a novel class of 1,4-dihydropyridines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Inhibition of IKs in guinea pig cardiac myocytes and guinea pig IsK channels by the chromanol 293B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Azimilide dihydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Selective class III antiarrhythmic agents. 1 Bis(arylalkyl)amines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Is cardiac IKs a relevant drug target?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Biology of cardiac arrhythmias: ion channel protein trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Inhibition of IKs channels by HMR 1556.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Preparation, preparation, preparation: The influence of adrenergic agonism in cardiac ventricular repolarisation assays used in preclinical drug development and drug safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Ototoxic side-effects of the I(Ks)-channel blocker HMR1556.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Separation of the components of the delayed rectifier potassium current using selective blockers of IKr and IKs in guinea-pig isolated ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

A model for early afterdepolarizations: induction with the Ca2+ channel agonist Bay K 8644.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

The KCNQ1 potassium channel: from gene to physiological function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Pulmonary vasoconstrictor action of KCNQ potassium channel blockers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Slow delayed rectifier potassium current (IKs) and the repolarization reserve.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Structure of KCNE1 and Implications for How It Modulates the KCNQ1 Potassium Channel † ‡

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Ranolazine: a review of its use in chronic stable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Alfuzosin delays cardiac repolarization by a novel mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Role of slow delayed rectifier K+-current in QT prolongation in the alloxan-induced diabetic rabbit heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

QT interval prolongation and torsade de pointes associated with indapamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Benchmarking safety pharmacology regulatory packages and best practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Both beta-adrenergic receptor stimulation and cardiac tissue type have important roles in elucidating the functional effects of I(Ks) channel blockers in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Potassium channel antagonists influence porcine granulosa cell proliferation, differentiation, and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Molecular basis of voltage-dependent potassium currents in porcine granulosa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

An immunohistochemical and electrophysiological study on Isk protein in the stria vascularis of the guinea pig

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

The QT syndromes: long and short

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Long QT syndrome: from channels to cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Reconstruction of the repolarization process in cardiac Purkinje fibres based on voltage clamp measurements of membrane current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Selective potentiation of L-type calcium channel currents by cocaine in cardiac myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Genetic testing in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Drug-induced prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Molecular determinants of KCNQ1 channel block by a benzodiazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Identification of specific pore residues mediating KCNQ1 inactivation. A novel mechanism for long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Slow delayed rectifier K+ current block by HMR 1556 increases dispersion of repolarization and promotes Torsades de Pointes in rabbit ventricles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

In vivo canine cardiac electrophysiologic profile of 1,4-benzodiazepine IKs blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Predictive models for HERG channel blockers: ligand-based and structure-based approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

QT interval, cardiovascular risk factors and risk of death in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Inner ear defects induced by null mutation of the isk gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Mode of onset of torsade de pointes in congenital long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Pharmacological antagonism of the slow-activating delayed rectifying potassium channel (I(Ks)) has no effect on cochlear structure and function in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

CAST: implications for drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

MinK-dependent internalization of the IKs potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

Long QT syndrome and short QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2009.04.197

10.1016/J.VASCN.2009.04.197

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference